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Abstract
Rheumatic autoimmune disorders are characterized by a sustained pro-inflammatory microenvironment associated with impaired func-
tion of endothelial progenitor cells (EPC) and concomitant vascular defects. Guanylate binding protein-1 (GBP-1) is a marker and intra-
cellular regulator of the inhibition of proliferation, migration and invasion of endothelial cells induced by several pro-inflammatory
cytokines. In addition, GBP-1 is actively secreted by endothelial cells. In this study, significantly increased levels of GBP-1 were detected
in the sera of patients with chronic inflammatory disorders. Accordingly we investigated the function of GBP-1 in EPC. Interestingly, stable
expression of GBP-1 in T17b EPC induced premature differentiation of these cells, as indicated by a robust up-regulation of both Flk-1
and von Willebrand factor expression. In addition, GBP-1 inhibited the proliferation and migration of EPC in vitro. We confirmed that
GBP-1 inhibited vessel-directed migration of EPC at the tissue level using the rat arterio-venous loop model as a novel quantitative 
in vivo migration assay. Overall, our findings indicate that GBP-1 contributes to vascular dysfunction in chronic inflammatory diseases
by inhibiting EPC angiogenic activity via the induction of premature EPC differentiation.
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Introduction
Blood vessel formation in adults may proceed through various
pathways. The primary mechanism is angiogenesis by either
sprouting or intussusception, both being vascular endothelial
growth factor (VEGF)-dependent processes [1, 2]. In addition, a
VEGF-independent mechanical or looping angiogenesis has been
described [3]. Vasculogenesis, previously regarded to be exclu-
sively involved in vessel formation in the embryo, has also been
shown to contribute to vessel formation in adults. This process
involves the recruitment of endothelial progenitor cells (EPC)
released from the bone marrow and incorporated into growing
vessels in adults [1, 4]. The molecular characteristics and the iso-
lation of these cells are still a matter of debate [5].
The most commonly used EPC markers are CD34, vascular
endothelial cell growth factor receptor 2 (VEGF-R2/Flk-1), Tie2,
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stem cell antigen-1 and CD133 (AC133). However, none of these
molecules is specific for EPC [5, 6]. Because of their low abun-
dance (0.01 to 0.0001%), the isolation of EPC is technically diffi-
cult [5]. In addition, mature endothelial cells, probably released
from vessel walls, circulate in the peripheral blood and share com-
mon markers with the EPC [5, 6]. A large body of evidence indi-
cates that EPC contribute to the formation of new vessels upon
vascular injury, chronic inflammatory, hypoxic conditions and
tumour growth [7–10].
In the rheumatic autoimmune disorders rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE) and systemic sclerosis
(SSc), reduced numbers of circulating EPC have been described
[11-14]. In RA, these cells display impaired migratory capabilities
[13], possibly contributing to endothelial dysfunction associated
with the increased cardiovascular morbidity and mortality com-
monly observed in these patients [15]. The molecular mechanism
of EPC dysfunction is elusive. It has been suggested that chronic
inflammation and increased levels of the pro-inflammatory
cytokines interferon (IFN)-/, tumour necrosis factor (TNF)- or
interleukin (IL)-1/ [16–18] may be involved in this process.
This was partly confirmed by the finding that anti-TNF- treatment
restored EPC levels in RA patients [19].
Guanylate binding protein-1 (GBP-1) is a member of the fam-
ily of large GTPases, which includes antiviral Mx proteins and the
caveolae regulatory molecule dynamin [20–24]. GBP-1 expression
is induced in endothelial cells by IFN-/-, IL-1/- and TNF-
[25] and mediates the potent anti-angiogenic effects of these
cytokines, both in vitro and in vivo [26–28]. It inhibits endothelial
cell proliferation, migration and invasiveness in vitro [26–28]. The
anti-angiogenic effect of GBP-1 has recently been confirmed in
colorectal carcinoma patients, where it was associated with sus-
tained reduction of intratumoral angiogenic activity and improved
cancer-related survival [29]. Interestingly, GBP-1 was described
as the first GTPase secreted from endothelial cells. Secretion
occurs via non-classical secretion pathways and was confirmed 
in vivo by the detection of increased GBP-1 concentrations in the
cerebrospinal fluid of patients with bacterial meningitis [30].
Here we show that the levels of GBP-1 are increased in sera of
patients with the rheumatic autoimmune diseases RA, SLE and
SSc, which are characterized by chronic inflammatory vessel acti-
vation. We provide experimental evidence that GBP-1 is directly
involved in the endothelial dysfunction and the regulation of EPC
activity.
Materials and methods
Patient characteristics
Patients with SLE from the outpatient clinic of the Department of Internal
Medicine 3 of the Erlangen University Medical Center met the diagnostic
criteria of the American College of Rheumatology [31]. Patients with RA
were from the Division of Rheumatology of the University of Heidelberg
that met the diagnostic criteria of the American College of Rheumatology
[32]. Control samples were obtained from normal healthy volunteers. The
study was approved by the Institutional Review Boards of the University of
Erlangen – Nuremberg and Heidelberg. Written informed consent was
obtained from all individuals before entering the study.
SSc patients were from Spedali Civili di Brescia. All patients fulfilled the
criteria for SSc proposed by the American College of Rheumatology
according to the classification system proposed by LeRoy et al. [33].
Thirty-two patients (34.8%) had a diffuse cutaneous SSc, whereas 60
(65.2%) were affected by the limited cutaneous form of the disease.
Written consent was obtained by all of the patients included. A summary
of the main patient characteristics is presented in Table 1.
Cell culture and stable transfection
T17b murine embryonic EPC [34, 35] were cultured in DMEM (Invitrogen,
Carlsbad, CA, USA) with 20% foetal calf serum (Biochrom, Berlin,
Germany), 100 U/ml penicillin, 100 g/ml streptomycin, 0.1 mM -mercap-
toethanol, 1 mM non-essential amino acids and 2 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) buffer pH 7.5 (all purchased from
Invitrogen) at 37C in a humidified atmosphere at 5% CO2. EPC were main-
tained in T-75 culture flasks (Nunc, Wiesbaden, Germany) coated for at least
2 hrs with 0.1% bovine skin gelatine, type B (Sigma-Aldrich, Taufkirchen,
Germany) in phosphate-buffered saline (PBS) (Biochrom AG, Berlin,
Germany). The cells were subcultured using 1 0.5 g/l trypsin and 0.2 g/l
ethylenediaminetetraacetic acid in HBSS (trypsin/EDTA) (PAA, Pasching,
Austria) and passaged in a 1:8 ratio. Cells were counted using the CASY cell
counting system (Schärfe System, Model DT, Reutlingen, Germany). All
cells were regularly tested for mycoplasma infection by using MycoAlert
(Cambrex, Charles City, IA, USA); all results were negative.
EPC were seeded in pre-coated 6-well plates with a density of 1  105
cells/well and cultured for 24 hrs. EPC were transfected with 2 g plasmid
DNA using Effectene transfection reagent (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. The plasmids pMCV-2.2
(vector obtained from Mologen GmbH, Berlin, Germany) and pMCV-2.2-
Flag-GBP-1 were used [30]. All plasmids contained a G418-resistance
gene. Selection was performed with 500 g/ml G418 (PAA) for 10 days.
Control-EPC were pooled after selection. For GBP-1-EPC, single clones
were picked, subcultured and analysed for expression. Protein extracts of
confluent T-25 were stored at –20C until analysis.
Proliferation assay
Control- and GBP-1-EPC (4  103 cells) were seeded in 24-well plates, and
three wells per group were counted using the CASY cell counting system
(Schärfe System) after 3 hrs (day 0) for normalization. Every day until 
day 3 three wells of each group were counted. Proliferation is expressed 
as fold induction, and all experiments were performed in triplicates. One
representative experiment of at least three is shown.
Wound-healing assay
The wound-healing assay was performed as described previously [28].
Briefly, control- and GBP-1-EPC were grown on gelatine-coated 6-well plates
(Nunc) until confluence. Confluent cell monolayers of control- and GBP-1-
EPC were scratched using a sterile 1 ml pipette tip. The monolayers were
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NHD (n 	 80)
Age (mean 
 S.D.)* 31.8 
 11.6 years
Sex (females)† 43 (53.75%)
RA (n 	 50)
Age (mean 
 S.D.) 56.4 
 13.3 years
Females 37 (74%)
At least four criteria of the following seven criteria were fulfilled for each patient: 
Morning stiffness  1 hr
Arthritis of three or more joints (right/left PIP, MCP, wrist, elbow, knee, ankle and MTP joints)
Arthritis of wrist, MCP or PIP joint
Symmetric involvement of joints
RA-typical radiographic changes in the hands
Subcutaneous nodules
Positive serum rheumatoid factor
Activity parameter:
Disease activity score (28 joints)‡ Remission  2.6 19 (38%)
Low activity  3.2 12 (24%)
Moderate activity 3.2–5.1 12 (24%)
High activity  5.1 3 (6%)
Erythrocyte sedimentation rate (ESR; mean 
 S.D.)# 19.7 
 18.2 mm/hr
C-reactive protein (mg/l)§ 2 mg/l 15 (30%)
2–10.0 mg/l 26 (52%)
10.1–40 mg/l 6 (12%)
40 mg/l 1 (2%)
SLE (n 	 51)
Age (mean 
 S.D.) 40.2 
 12.8 years
Females 44 (86.3%)
ESR (mean 
 S.D.)# 28.0 
 21.9 mm/hr
C-reactive protein (mg/l)§ 2 mg/l 24 (47.1%)
2–10.0 mg/l 16 (31.4%)
10.1–40 mg/l 7 (13.7%)
40 mg/l 2 (3.9%)
Leukocytes (mean 
 S.D.) 6.5 
 3.5  103/l (normal: 4–10  103/l) 
Lymphocytes (mean 
 S.D.) 1.0 
 0.8  103/l (normal: 1.3–3.3  103/l)
Thrombocytes (mean 
 S.D.) 241.0 
 111.8  103/l (normal: 140–400  103/l)
Positive serum rheumatoid factor$ 11 (21.5%)
Table 1. Clinical and demographic characteristics of the NHD (n 	 80), RA (n 	 50), SLE (n 	 51) and SSc patients (n 	 92) analysed
Continued
J. Cell. Mol. Med. Vol 15, No 7, 2011
1585© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Autoantibody profile: Anti-dsDNA antibodies (Farr; U/ml) 7.0: 23 (45.1%); 7.0: 28 (54.9%)
Positive ANA titres 35 (68.6%)
Anti-cardiolipin (GPL U/ml)** 13: 22 (43.1%); 13: 10 (19.6%)
Positive lupus anticoagulant†† 14 (27.5%)
Anti-2-glycoprotein-1 (U/ml)‡‡ 10: 19 (41.2%); 10: 4 (7.8%)
Organ involvement
Joints 27 (52.9%)
Kidneys 22 (43.1%)
Skin 29 (56.9%)
Blood 21 (41.2%)
Vessels 5 (9.8%)
Serous membranes 13 (25.5%)
CNS 7 (13.7%)
SSc (n 	 92)
Age (mean 
 S.D.) 59.2 
 13.1 years
Females 82 (89%)
Disease duration 10.8 
 7.8 years
Cutaneous form Diffuse: 32 (35%) Limited: 60 (65%)
Autoantibody profile: Positive anti-nuclear antibodies 90 (97.8%)
Anti-topoisomerase I (anti-Scl70) 26 (28.3%)
Anti-centromere 30 (32.6%)
Anti-RNA polymerase III 8 (8.7%)
Pulmonary fibrosis on CT scan 38 (41.3%)
Restrictive lung disease (FVC, forced vital capacity 75%) 6 (6.5%)
Left ventricular ejection fraction 55% 5 (5.4%)
Diastolic left ventricular dysfunction based on E/A ratio 6 (6.5%)
History of renal crisis 4 (4.3%)
Prostacyclin endovenous therapy required for digital ulcerations 32 (34.8%)
Table 1. Continued
*Age of 10 donors was not registered.
†Sex of one donor was not registered.
‡DAS28 of four patients was not registered.
#ESR was not measured in five RA and two SLE patients.
§CRP was not measured in two RA and two SLE patients.
$Rheumatoid factor was not measured in 20 patients.
**Anti-cardiolipin was not measured in 19 patients.
††Lupus anticoagulant was not measured in 25 patients.
‡‡Anti-2-glycoprotein was not measured in 28 patients.
RA: rheumatoid arthritis; MCP: metacarpophalangeal; MTP: metatarsophalangeal; NHD: normal healthy donors; PIP: proximal interphalangeal; SLE:
systemic lupus erythematosus; SSc: systemic sclerosis.
1586 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
washed twice with PBS and cultured for 10 hrs in basal medium. Images of
the same areas were taken immediately after scratching (0 hr) and every 
2 hrs using an Olympus digital camera mounted on an Axiovert 25 microscope
(Zeiss, Jena, Germany). The width of the wounding scratches at different
time-points was measured and expressed as relative percentage of the initial
distance at 0 hr, which was set to 100%. All experiments were performed in
triplicates, and one representative experiment of at least three is shown.
Lactate dehydrogenase assay
Cell culture supernatants were taken of nearly confluent cells after 24 hrs.
The cell number was determined at the time of harvesting. The lactate
dehydrogenase activity assay was performed according to the manufac-
turer’s instructions (CytoTox 96 non-radioactive cytotoxicity assay,
Promega, Mannheim, Germany). The activity was normalized per 105 cells.
RNA isolation and RT-PCR
RNA isolation and RT-PCR was performed as previously described [24].
Briefly, total RNA of control- and GBP-1-EPC was isolated using the
RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.
Residual traces of genomic DNA were removed by DNase I (Qiagen) diges-
tion. RNA concentration and purity were determined photometrically
(GeneQuant, Amersham Biosciences, Freiburg, Germany), and RNA
integrity was controlled by non-denaturing agarose gel electrophoresis.
One microgram of total RNA from each sample underwent RT-PCR after
DNase treatment. Reverse transcription and cDNA synthesis was done
using SuperScript III Reverse Transcriptase (Invitrogen) followed by RT-
PCR analysis using 10 PCR buffer, 50 mM MgCl2, Platinum Taq DNA
polymerase and dNTPs (25 mM each) according to the supplemented pro-
tocols. The following primer pairs were used for the amplification of
murine reverse-transcribed products: von Willebrand factor (vWF): for-
ward 5-GTGAAGATTGGCTGCAACAC-3; reverse 5-TGTGCTTCAGGAC-
CACAGAG-3; flk (VEGFR-2): forward 5-ATTCAGGCATTGTACTGAGAG-3;
reverse 5-TCCAAGTTGGTCTTTTCCTG-3; glyceraldehyde-3-phosphate
dehydrogenase (mGAPDH): forward 5-GCCTCGTCCCGTAGA-3; reverse
5-GATGCATTGCTGACAATCTTG-3. The following primer pair was used for
the amplification of human GBP-1: forward 5-TCAGCTGACTTTGT-
GAGCTT-3; reverse 5-TCAGCCTGTATCCCCTTCCT-3. The murine flk
(VEGFR-2) and GAPDH primer pairs have been published previously [36].
All reagents were purchased from Invitrogen. Ten microlitres of each PCR
sample were electrophoresed on a 1% agarose gel containing ethidium
bromide. RT-PCR products were photographed under a UV transillumina-
tor and quantified using AIDA software (raytest, Straubenharth, Germany).
Western blot
Western blotting of Ripa cell lysates was performed as described previ-
ously [25, 30]. The following primary antibodies were incubated for 1 hr at
room temperature (RT): monoclonal rabbit anti-murine actin antibody
(1:1000; Sigma-Aldrich) and monoclonal rat anti-human GBP-1 antibody
(clone 1B1; 1:500; hybridoma supernatant). Detection of the primary anti-
bodies was performed with donkey anti-rabbit (GE Healthcare, Munich,
Germany) and rabbit anti-rat (Dako, Hamburg, Germany) immunoglobulin
G (IgG) coupled to horseradish peroxidase (HRP) (1:5000) for 45 min. at
RT. HRP detection was performed with enhanced chemiluminescence (ECL)
reagents (GE Healthcare) and x-ray films (Fuji, Düsseldorf, Germany).
Immunocytochemistry
Immunocytochemistry was performed as previously described [37]. Briefly,
for all stainings the cells were cultured on gelatine-coated culture slides (BD
Biosciences, Heidelberg, Germany) until they reached confluence. All slides
were washed with PBS once and fixed in ice-cold ethanol for at least 20 min.
Cells were rehydrated and blocked with 10% goat normal serum (GNS)
(Dianova, Hamburg, Germany) in TBS. Afterwards, incubation with a mon-
oclonal rat anti-human GBP-1 antibody (clone 1B1; hybridoma supernatant;
1:100 in 5% GNS in TBS) was done for 2.5 hrs. Subsequently, goat anti-rat
immunoglobulin (Alexa 488; Invitrogen, Karlsruhe, Germany 1:500 in 5%
GNS in TBS) was added for 1 hr. Nuclei were counterstained with 4,6-
diamidin-2'-phenylindol-dihydrochloride (DAPI) (Invitrogen; 1:5000 in A.d.)
for 20 min. Slides were mounted with fluorescence mounting medium
(Dako) and photographed using an Aristoplan microscope (Leica
Microsystems, Bensheim, Germany).
Differentiation of control- and GBP-1-EPC
Differentiation of EPC was induced by the application of differentiation
medium (DM) containing retinoic acid and cyclic adenosine monophos-
phate (cAMP) on four consecutive days following a previously described
protocol [34]. In brief, the DM was generated by supplementing normal
medium with 0.5 mM dibutyryl cAMP (Sigma-Aldrich Chemie, Schnelldorf,
Germany) and 1 M retinoic acid (Sigma Aldrich Chemie). Control- and
GBP-1-EPC (1  106 cells) were seeded in pre-coated T-75 cell culture
flasks (Nunc), and DM was added 5 hrs later. EPC were cultured with DM
for 4 days. DM was refreshed each day. On day 5 the EPC were detached,
counted using the automatic CASY cell counting system (Schärfe System)
and lysed for RNA extraction. Lysates were stored at –80C until analysis.
Supernatants of the last 24 hrs were taken and stored at –80C until analy-
sis. As a control, 3.5  105 control- and GBP-1-EPC were cultured in pre-
coated T-75 cell culture flasks (Nunc) with normal culture medium until
they reached confluence. The non-differentiated cells were treated identi-
cally to the differentiated cells except for the lack of DM.
GBP-1-ELISA
Cell culture supernatants were taken of nearly confluent cell layers after 
24 hrs and analysed in triplicates by GBP-1-ELISA according to a previously
described protocol [30]. The cell number was determined at the time of har-
vesting. Serum samples were analysed in triplicates using the same protocol
except with diluting the samples 1:8 before analysis. The colour reaction was
measured in a microplate reader (Model 680; Bio-Rad, Munich, Germany).
The results shown are depicted as means 
 S.D. and are normalized to the
corresponding cell number for the cell culture supernatants.
Labelling of EPC
EPC were labelled using the Cell Tracker CM-DiI (Molecular Probes, Leiden,
Netherlands). Accordingly, 1 mg DiI was dissolved in 1 ml dimethyl sulfox-
ide (DMSO), and 25 l of this stock were diluted in 10 ml of normal cul-
ture medium. Cells of a T-75 flask were incubated with the DiI-medium
solution and kept at 37C for 5 min., followed by 4C for 15 min. After this
procedure, the cells were detached, counted with the CASY cell counting
system, and used for the experiments.
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Arterio-venous loop (AV-loop) in the rat model
system – experimental design and animals
Chambers containing 5  106 control- or GBP-1-EPC suspended in 500 l
fibrin gel were implanted (n 	 8). The explantation was performed 14 days
after the implantation of the constructs. Syngenic male Lewis rats (Charles
River Laboratories, Sulzfeld, Germany) with a mean weight of 250 
 50 g
were used in this study. The German regulations for the care and use of
laboratory animals were followed at all times. All experiments were
approved by the animal care committee of the University of Erlangen and
the Government of Mittelfranken, Germany. The animals were housed in
the veterinary care facility of the University Medical Center Erlangen and
submitted to a 12 hr dark/light cycle with ad libitum access to standard
chow (Altromin, Hamburg, Germany) and water.
Isolation chamber and composition 
of the fibrin matrix
The cylindrical chamber (inner diameter 10 mm, height 6 mm) with a
rounded lid was made of heat-resistant medical-grade teflon (P. Greil,
Department of Materials Science, Glass and Ceramics, University of
Erlangen). In this study, the matrix was composed of a clinically approved
fibrin gel (Tissucol, Baxter, Unterschleissheim, Germany) with a fibrinogen
concentration of 10 mg/ml, a thrombin concentration of 2 IU/ml and an
aprotinin concentration of 1500 KIE/ml to delay fibrinolysis.
Generation of the AV-loop
Operations were performed as previously described [38–40]. Briefly, all
operations were performed by the same microsurgeon using an operative
microscope (Zeiss) on rats under general anaesthesia with isoflurane
(Baxter). The left femoral vessels were exposed by a longitudinal skin inci-
sion from the groin to the knee. The artery and vein were dissected from
the pelvic artery in the groin to the bifurcation of the femoral artery in the
knee. A 20 mm vein graft was harvested from the right femoral vessels.
This vein graft was interposed between the recipient left femoral vein and
artery by microsurgical techniques using 11–0 sutures (Ethicon,
Norderstedt, Germany). The chamber was filled with 250 l fibrin gel, and
the AV loop was passed around the four plastic sticks. Then, the chamber
was filled with the second half of the fibrin gel-matrix to a total volume of
500 l, the lid was closed and the chamber was fixed in the groin using
Prolene 3–0 (Ethicon) sutures. Haemostasis was assured, and the wound
was closed using Vicryl 3–0 (Ethicon). Post-operatively, all animals
received 0.4 ml long-term penicillin dihydrostreptomycin (aniMedica
GmbH, Senden-Bösensell, Germany), buprenorphin (0.3 mg/kg body
weight, Temgesic, Essex Chemie AG, Luzern, Switzerland) and heparine
(80 IU/kg Liquemin, Ratiopharm, Germany).
Histological analysis
The animals were perfused with Microfil prior to explantation of the con-
structs. The abdomen was opened via a midline incision, and the aorta and
inferior vena cava were exposed. After cannulation of the distal descending
aorta using a 24-gauge catheter, the rats were flushed with 100 ml heparin
solution in Ringer buffer (100 I.E./ml) until the returning fluid from the sev-
ered inf. vena cava was clear. Then, 20 ml yellow Microfil (MV-122) con-
taining 5% MV Curing Agent (both Flowtech, Carver, MA, USA) were
injected. Finally, the aorta and caval vein were ligated, and the rats were
cooled at 4C for 24 hrs.
The constructs were fixed in 4% formalin solution for 12 hrs, dehy-
drated in graded ethanol and embedded in paraffin. Cross-sections (3 m)
were obtained using a Leica microtome (Leica Microsystems) after the
constructs were cut in the middle. Planes were oriented rectangular to the
longitudinal axis of the AV loop. Cross-sections were stained either using
haematoxylin/eosin or DAPI (Invitrogen).
The images were evaluated by two independent and blinded observers.
All images were generated with a Leica microscope and digital camera.
Scale bars are given in the respective figures.
Statistical analysis
The Mann-Whitney U-test and Student’s t-test for independent samples
were performed with SPSS 15.0 software (SPSS Inc., Chicago, IL, USA).
Level of significance was defined at P  0.05.
Results
Sera levels of GBP-1 are increased in patients
with systemic autoimmune diseases
Sera were drawn from patients suffering from RA, SLE or SSc,
which are autoimmune diseases displaying severe inflammation
and are known for having endothelial dysfunction. The main
patient characteristics for all of the cohorts are summarized in
Table 1. GBP-1 serum levels were quantified by ELISA and com-
pared to sera of normal healthy donors (NHD). GBP-1 levels were
significantly increased in all patient cohorts compared to the con-
trol group (Fig. 1, asterisks given for P  0.05). The GBP-1 serum
levels for RA, SLE, SSc and NHD were 190.6 
 301.6 ng/ml 
(RA, n 	 50, P  0.001), 75.2 
 188.0 ng/ml (SLE, n 	 51, 
P 	 0.036), 87.5 
 295.2 ng/ml (SSc, n 	 92, P 	 0.027) and 
17.5 
 43.9 ng/ml (NHD, n 	 80), respectively. The relative num-
bers of samples with GBP-1 concentrations higher than two stan-
dard deviations above the mean of the control group (Fig. 1, dashed
line) were at least six times increased in the cohorts of autoimmune
patients (RA: 40.0%, SLE, 17.6%; SSc, 15.2%; NHD 2.5%).
GBP-1 induces premature differentiation of EPC
GBP-1 expression in tissues is closely associated with endothelial
cells [25]. In this framework it was interesting that impaired func-
tions of circulating EPC have been described in patients with rheu-
matic autoimmune disorders [11–14]. Therefore, we aimed to
investigate the function of GBP-1 in EPC. GBP-1 cDNA was stably
expressed in the murine endothelial embryonic progenitor cell line
T17b in order to investigate the role of GBP-1 in a well-defined
1588 © 2011 The Authors
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experimental model for EPC. Three cell clones, which exhibited
GBP-1 expression levels similar to those observed in IFN--
treated human endothelial cells [26–28] (Fig. 2A, GBP-1) were
selected and pooled for further studies. The cell population
obtained showed a purity of more than 95% when GBP-1 expres-
sion was analysed at the single cell level by immunocytochemistry
(Fig. 2B, GBP-1 pool). The control cells (control-EPC) stably trans-
fected with the empty vector did not show any signal in analyses
by Western blotting (Fig. 2A) or immunocytochemistry (Fig. 2B).
Culture supernatants showed significantly elevated GBP-1 con-
centrations in GBP-1-transfected cells by ELISA (Fig. 2C, left). Cell
lysis was not increased under these conditions, as shown by the
quantification of lactate dehydrogenase in the same supernatants
(Fig. 2C, right). The amount of GBP-1 present in the supernatant
of GBP-1-EPC was similar to the amount previously described to
be actively secreted from IFN--stimulated HUVEC within the
same period of time [30]. These results indicated that EPC simi-
larly as differentiated endothelial cells secrete GBP-1, which may
contribute to increased serum concentrations of this protein in
patients with rheumatic autoimmune disorders.
Differentiation of T17b cells can be induced by treatment with
cAMP and retinoic acid [34]. Analysis by immunocytochemistry
showed that the induction of differentiation did not affect GBP-1
expression levels in these cells (Fig. 3A, compare differentiated [diff.]
and undifferentiated [undiff.] cells). However, differentiated cells
were enlarged and cell numbers were reduced, irrespective of GBP-1
expression (Fig. 3A). The same phenotypical changes (enlargement
and reduced number of cells) were observed in differentiated control
cells in the absence of GBP-1 expression (data not shown).
It has been shown that differentiation of T17b cells increases
the expression of vascular endothelial growth factor receptor 2
(VEGF-R2/Flk-1) and vWF [34]. This was confirmed by RT-PCR in
control cells after treatment with cAMP and retinoic acid (Fig. 3B,
left part, compare [–] and [] differentiation). Interestingly, in
cells stably expressing GBP-1, the expression of both factors was
increased to similar levels in the absence of cAMP and retinoic
acid (Fig. 3B, right part, [–]) In line with this observation, expres-
sion levels of both factors were slightly up-regulated in GBP-1-
transfected cells upon treatment with cAMP and retinoic acid 
(Fig. 3B, right part []). GBP-1 expression was not altered by
treatment with cAMP and retinoic acid (Fig. 3B), and GAPDH 
levels demonstrated that equal amounts of RNA had been loaded
(Fig. 3B). Quantitative evaluation of the results confirmed that
induction by GBP-1 of both vWF and Flk-1 expression was similar
Fig. 1 GBP-1 levels are increased in sera of patients with the autoimmune
diseases, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or
systemic sclerosis (SSc). GBP-1 was quantified by ELISA [30] in serum
samples of patients suffering from RA (n 	 50), SLE (n 	 51), SSc (n 	
92) and NHD (n 	 80). A vertical scatter plot is given with a line correspon-
ding to the mean values. A dashed line indicates the mean of the NHD plus
two standard deviations. A t-test for independent samples was used to deter-
mine significance (asterisks given for P-values  0.05). Non-detectable
(n.d.) indicates GBP-1 values below the detection limit of the ELISA.
Fig. 2 Detection of GBP-1 expression and secretion in stably transfected
EPC. (A) Western blot analysis of total cell lysates obtained from EPC clones
stably transfected with control-vector pMCV-2.2 (control-EPC) or with flag-
tagged GBP-1 (GBP-clones 1, 2 and 3). Immunochemical detection of actin
demonstrates equal protein loading. (B) Control- and GBP-1-EPC were
stained by immunocytochemistry for GBP-1 using a monoclonal rat anti-
human GBP-1 antibody (clone 1B1) and an Alexa488-labelled secondary
antibody. GBP-1-staining is visualized by green colour. Counterstaining was
performed with DAPI (blue). (C) Extracellular GBP-1 was quantified in the
culture supernatants of control- and GBP-1-EPC by ELISA. Non-specific
leakage of intracellular proteins was estimated by quantification of lactate
dehydrogenase activity (U/L) in the cellular supernatants using a commercial
assay. All results are given as means 
 S.D. and are normalized to the cell
numbers (105 cells) releasing the indicated amount over 24 hrs.
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to that observed after standard treatment for differentiation (Fig. 3,
lower-left panel, compare black [GBP-1] and white [control] bars;
lower-right panel, white [undifferentiated], black [differentiated]).
Overall, these results clearly indicate that GBP-1 expression was
sufficient to induce the differentiation of EPC.
GBP-1 inhibits proliferation and migration 
of EPC in vitro
The proliferative and migratory behaviours of control- and GBP-1-
EPC were investigated to evaluate whether GBP-1 expression
impaired the EPC phenotype. Proliferation of GBP-1-EPC was
significantly (P  0.05) inhibited compared to control-EPC 
(Fig. 4A). Moreover, time-course analysis employing the wound-
healing assay showed that migration of GBP-1-EPC was signifi-
cantly inhibited compared to control-EPC (Fig. 4B). The results
obtained after 10 hr incubations clearly demonstrate the reduced
capability of GBP-1-EPC to recultivate the wounded areas (Fig. 4C).
GBP-1 inhibits the migration of embryonic 
EPC in vivo
The migratory potential of the GBP-1-expressing and GBP-1-non-
expressing T17b cells in vivo was studied in the AV-loop model of
Fig. 3 After in vitro differentiation, GBP-1 expression is stably maintained
and promotes EPC differentiation. (A) Staining of undifferentiated (Undiff.)
and differentiated (Diff.) GBP-1-EPC by immunocytochemistry was per-
formed with a rat anti-human GBP-1 antibody (green). Counterstaining was
performed with DAPI (blue). (B) Semi-quantitative RT-PCR was performed
to quantify RNA expression levels of Flk-1, vWF, GBP-1 and GAPDH in con-
trol- and GBP-1-EPC before (–) and after () differentiation. Decreasing
amounts of cDNA (undiluted, 1:10, 1:100, 1:1000) were subjected to PCR
after reverse transcription of the isolated RNA. Bands obtained at non-sat-
urated levels were quantified by densitometry and normalized to the corre-
sponding GAPDH signal. Results are given as fold change.
Fig. 4 GBP-1 reduces the proliferation and migration of EPC in vitro. (A)
Control- and GBP-1-EPCs were cultured for 3 days after initial seeding of
the same cell number and were counted every day with a Casy counter
upon harvesting. Cell proliferation is expressed as fold induction. One rep-
resentative experiment of at least three is shown, and data points are given
as means 
 S.D. Asterisks indicate P-values  0.05. (B) The migratory
capacity of control- and GBP-1-EPC was investigated using a wound-heal-
ing assay. In vitro scratch wounds were generated by scraping a confluent
cell monolayer with a sterile pipette tip. Pictures from the same areas were
taken immediately after scratching (0 hr) and then every 2 hrs. The width
of the scratch wounds at the time-points indicated was analysed and com-
pared to the initial width. The values are displayed as relative percentages.
Results are given as means 
 S.D. of one representative of at least four
experiments. Asterisks indicate P-values  0.05. (C) Representative
pictures of the scratch assay acquired at time-points 0 and 10 hrs of
Control- and GBP-1-EPC.
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rats [40]. This method provides an in vivo compartment with
defined size and similar initial vasculature as defined by the AV-
loop, in contrast to other presently available in vivo tests, such as
matrigel transplantation.
Equal amounts of DiI-labelled GBP-1- or control-EPC (5  106
cells) were inoculated as a fibrin suspension into AV-loop cham-
bers (n 	 8). After 14 days, the chambers were explanted and
subjected to immunohistochemical analyses. Cross-sectioning
and haematoxylin/eosin staining showed the central vessels (CV;
Fig. 5A) of the AV-loop separated by the fibrin clot (FC) containing
the EPC (Fig. 5A, FC). A fibrovascular tissue sheath (Fig. 5A, T)
had developed, surrounding the CV.
EPC show directed migration to increasing oxygen gradients
[41]. To determine the oxygen-directed migratory capacity of the
implanted EPC, the numbers of DiI EPC were determined in
defined squares (0.01 mm2) at three increasing distances (four
squares at each distance) relative to the CV in representative tissue
sections of each chamber (GBP-1-EPC, n 	 4; control-EPC, n 	 4).
At the close distance (0–135 m), the number of GBP-1-EPC was
significantly reduced compared to the control-EPC (Fig. 5B). In
contrast, at the largest distance (135 m), cell densities of GBP-
1-EPC and control-EPC were not statistically different (Fig. 5B).
Representative histological pictures demonstrate this fact (Fig. 5C).
GBP-1-EPC showed a clearly reduced capability to immigrate into
the fibrovascular sheath towards increasing oxygen concentrations
compared with control-EPC (Fig. 5C, compare GBP-1, DiI and con-
trol, DiI). The absolute numbers of cells present in the tissues did
not differ in chambers filled with control-EPC or GBP-1-EPC, as
indicated by DAPI staining (Fig. 5C, DAPI, P 	 0.474).
Discussion
GBP-1 is the first GTPase shown to be secreted by cells [30].
Unfortunately, its extracellular function is still unclear. It has been
shown that GBP-1 is selectively secreted by endothelial cells
exposed to the inflammatory cytokines IFN-/, IL-1/ and TNF-
[30]. Increased serum concentrations of these cytokines are charac-
teristically detected in patients with rheumatoid autoimmune disor-
ders [16–18]. Consequently, activated endothelial cells have been
detected in these patients at the tissue level, indicated by increased
expression of the inflammation-associated proteins intercellular
adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule
1 (VCAM) [42, 43]. Here, we show that GBP-1 serum levels may be
used as a serologic marker for generalized inflammatory endothelial
cell activation. Significantly increased serum levels of GBP-1 were
detected by ELISA in patients with RA, SLE and SSc, as compared
to healthy controls. The most robustly increased GBP-1 serum con-
centrations were observed in patients with RA (190.6 
 301.6 ng/ml
[RA] versus 17.5 
 43.9 ng/ml [NHD]). In NHD and RA patients,
2.5% and 40% of the sera, respectively, contained more than 
105.2 ng/ml GBP-1 (mean of NHD  2 S.D.). These results identify
GBP-1 as a novel biomarker for the detection of generalized inflam-
matory activation of endothelial cells in patients with rheumatic
autoimmune disorders and favour the notion that IFN-inducible
genes are involved in the etiopathogenesis of these diseases.
Consistent with this notion, we recently reported that auto-antibod-
ies against another IFN-inducible protein, the pro-inflammatory
interferon, gamma-inducible protein 16 (IFI16), are significantly
increased in patients with SSc, SLE and Sjogren syndrome [44, 45].
GBP-1 inhibits endothelial cell proliferation, migration and
invasion [26–28], and inhibiting its expression abrogates these
effects in endothelial cells exposed to inflammatory cytokines
[16–18]. These findings established GBP-1 as the intracellular
mediator of the anti-angiogenic effects on endothelial cells of
inflammatory cytokines. Its anti-angiogenic activity has been con-
firmed in patients with colorectal carcinoma, where GBP-1 expres-
sion in tumour endothelial cells was associated with reduced
angiogenic activity and significantly prolonged cancer-related sur-
vival of the patients [29]. Considering the anti-angiogenic effect of
GBP-1 it is interesting that patients with rheumatic autoimmune
diseases often present with cardiovascular dysfunction. This has
mainly been attributed to the EPC system, which is often impaired
Fig. 5 Stable expression of GBP-1 reduces the migratory capacity of EPC in
an in vivo AV-loop rat model. (A) Overview of an explant of the AV-loop
chamber stained by haematoxylin/eosin. Letters indicate the anatomical
structures central vessels (CV), fibrovascular tissue (T), and fibrin clot (FC),
with the remaining being EPC. Scale bar 	 1 mm. (B) The number of DiI
cells/0.01 mm2 tissue area was quantified in three relative distances to the
CV at four different sites of each explant (n 	 4 for each group). The values
are depicted by a vertical scatter plot with a line corresponding to the mean.
Asterisks are given for P-values  0.05; n.s. indicates not significant. (C)
DiI Control- and GBP-1-EPC were visualized by epifluorescent microscopy
(red). Counterstaining was performed with DAPI (blue). The lumen of the CV
is indicated by a white line in the consecutive pictures. Different magnifica-
tions of the same areas are displayed (left versus right panel). The absolute
numbers of cells in the DAPI channel were counted in at least three optical
fields for both, the Control- and GBP-1-EPC, statistically evaluated and were
not found to be significantly different (P 	 0.474). Scale bars 	 250 m.
J. Cell. Mol. Med. Vol 15, No 7, 2011
1591© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
in these patients. The impact of GBP-1 on vasculogenic activities
mediated by EPC has not been determined. In order to investigate
this, we used a well-characterized EPC line, T17b, which can eas-
ily be transfected and differentiated by adding cAMP and retinoic
acid in vitro [34]. The major cellular markers indicating EPC differ-
entiation are Flk-1 and vWF. We found that both markers were
strongly up-regulated in GBP-1-expressing EPC, indicating that
GBP-1 is sufficient to induce premature differentiation of these
cells. This finding is consistent with previous studies detecting cir-
culating mature endothelial cells proposed to be released from
vessel walls by shedding [5, 6].
GBP-1-induced EPC differentiation also impaired their vasculo-
genic activities by inhibition of their proliferation and migration 
in vitro. As yet, not many assays are available to quantify the migra-
tory activities of cells in vivo. Matrigel-implant tests are often ham-
pered by the fact that the pre-existing vasculature and volume
spread of injected matrigel cannot be defined precisely [46]. To
overcome these limitations, the rat AV loop model was established
as a novel test system to investigate the migratory capability of EPC
in vivo. In the AV loop model the vasculature is precisely defined by
the vascular loop, and the reaction chamber permits the application
of a defined amount of matrix in a defined structure with defined
numbers of cells. As endothelial cells migrate along oxygen gradi-
ents in vivo [41], the migration of the applied EPC from the FC into
the fibrovascular sheaths of the AV loop CV can be used to quan-
tify cell migration. Employing this novel technology, we showed
that control-EPC invaded the fibrovascular sheath significantly
more efficiently than GBP-1-EPC cells. This confirmed that GBP-1
inhibits the migratory capability of EPC in vivo.
Taken together, our data establish circulating GBP-1 as a novel
biomarker for inflammatory vessel activation in rheumatic autoim-
mune diseases. Mechanistically, GBP-1 induces the premature dif-
ferentiation of EPC and inhibits the vasculogenic activities of EPC.
Both effects most likely contribute to the cardiovascular defects
observed as a major pathological impact in chronic autoimmune
inflammatory diseases.
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